Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

OncoCyte Corporation (OCX)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
0.3900+0.0020 (+0.52%)
At close: 04:00PM EST
0.4000 +0.01 (+2.56%)
After hours: 06:03PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close0.3880
Open0.3700
Bid0.3730 x 4000
Ask0.4000 x 800
Day's Range0.3700 - 0.4000
52 Week Range0.2420 - 1.7500
Volume252,152
Avg. Volume396,659
Market Cap46.271M
Beta (5Y Monthly)1.70
PE Ratio (TTM)N/A
EPS (TTM)-0.7710
Earnings DateMar 08, 2023 - Mar 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.83
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for OCX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • OncoCyte Corporation
    Daily – Vickers Top Insider Picks for 09/27/2022The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
    Rating
    Fair Value
    Economic Moat
    4 months agoArgus Research
View more
  • MarketWatch

    Oncocyte cuts 40% of staff

    Oncocyte Corp. shares rose 5% in premarket trades after the Irvine, Calif., molecular diagnostics company for the detection of cancer, said it would reduce more than 40% of its workforce "to align its team towards key products that address larger markets." As of Dec. 31, 2021, the company employed full-time 110 people, according to Oncocyte's annual report. The positions of Gisela Paulsen, president and chief operating Officer, and Douglas Ross, chief scientific officer, will be eliminated. Onco

  • GlobeNewswire

    Oncocyte Announces Initiatives to Focus Corporate Strategy

    IRVINE, Calif., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving over 40% of Oncocyte’s workforce to realign its team towards key products that address larger markets. Additionally, Oncocyte has entered into a Stock Purchase Agreement pursuant to which Oncocyte will transfer 70% of its ownership of Razor Genomics, Inc. to buyers who are leaders in the development of early stage lung cancer diagno

  • GlobeNewswire

    Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors

    IRVINE, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced the appointment of Louis E. Silverman as an independent member of its board of directors, effective immediately. “I am pleased to announce the appointment of Lou as a member of our Board,” said Andy Arno, Chair of Onco

Advertisement
Advertisement